Business, Entertainment, Free News Articles

‘Besos de plastico’ Documentary is a Doctor Alert About Botched Faces From Illegal Injections

MADRID, Spain -- As an amateur social project of the famous Dominican plastic surgeon, Luis Lopez Tallaj MD, trained in Brazil 20 years ago, has released recently on YouTube, the dramatic documentary "Besos de plástico" (Plastic Kisses). It is already available on his YouTube channel Lopeztallaj, this Hispanic or Latin project with closed captions in English, French and Portuguese is a warning to the global population of the risks taken with biopolymers injections.

In "Plastic Kisses," the Dominican plastic surgeon, alerts about the complications involved in the secrecy of the injections of alloplastic material, which have left more than a million victims with facial and corporal consequences in Iberoamerica from the disease known as Iatrogenic Alogenosis.

Testimonies from victims, wake-up calls of surgeons from both continents, possible correction of deformities, the procedure of lip harmonization and more, to create awareness and the prevention of more victims.

"In just ten minutes the spectator can have a very accurate idea of the message we want to spread, warning and prevention," said Dr. L. Tallaj.

To learn more and watch the documentary visit: https://youtu.be/dXzU6PM_qUI

Dr. Luis López Tallaj @lopeztallaj was born in the city of Santiago de Los Caballeros in 1971 in the north of the Dominican Republic.

Graduated as a doctor of medicine from the Pontificia Universidad Católica Madre y Maestra in 1995. He is Head of the Department of Plastic Surgery at the Corazones Unidos Clinic in Santo Domingo, and founder of the prestigious Institute of Anti-Aging Medicine Puntacana Rejuvenation Center.

He completed his specialty in Aesthetic and Reconstructive Plastic Surgery at the Santa Casa de la Misericordia General Hospital in the City of Rio de Janeiro in Brazil 20 years ago. Specialist in Anti-Aging Medicine from the University of Seville.

At the American Society for Aesthetic Plastic Surgery, he was Chair of the International Committee from 2011 to 2016. Member of the ASPS and ASAPS.

He is the only Hispanic member of the United States Physicians Coalition for Injectable Safety.

He is also an author who has previously published three books, as well as the first guide on healthy infant feeding "Eat and Grow" which is available in 7 languages ​​on Amazon now.

MEDIA ONLY CONTACT:

Luis Lopez Tallaj MD

+34 666 71 04 91

Info@drlopeztallaj.com

https://drlopeztallaj.com/

Imagen entre líneas

Siguenos en Instagram @Chipjuventud

https://chipjuventud.com/

Related link: https://drlopeztallaj.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

The research is being led by Drs. Oriol Bestard and Rico Buchli and focuses on the detection of alloreactive memory B cells for pre-transplant risk stratification and post-transplant monitoring. Recognition of non-self HLA gives rise to the formation of HLA-specific memory B cells which precede circulating HLA antibodies. Importantly, such HLA-specific memory B cells can be present even in the absence of detectable serum antibodies, being an additional rejection risk factor in transplantation. Memory B cells are responsible for immunological recall responses by differentiating into antigen-specific antibody-producing cells upon re-encounter with a miss-matched antigen.

"This collaboration with PTS validates the tremendous need for appropriate and routinely applicable assays to detect and visualize the presence and HLA specificity of alloreactive memory B cells in solid organ transplant patients, which may ultimately help improve current alloimmune-risk stratification," Dr. Bestard stated.

"Today, the immunological risk of an individual transplant patient is mainly assessed by detection of HLA antibodies in the serum, which are produced by long lived bone marrow-residing plasma cells. At PTS, we envision that in addition to serum HLA antibody detection, HLA-specific memory B cell assays will serve as supplemental tools to determine risk factors and help improve individual patient management," said Dr. Buchli.

Steve Mayer MD, Chief Medical Officer at PTS stated, "We're very excited about the potential of this technology because it allows a very early diagnostic view of an individual's risk of rejection before any graft damage has occurred. Also, the technology is likely to have a significant impact on clinical utility with high predictive values."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its ecommerce website, https://www.hlaprotein.com/, Pure Protein offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Vall d'Hebron Barcelona Hospital Campus

We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management. The Vall d'Hebron Barcelona Hospital Campus is the combination of our five entities: the Vall d'Hebron University Hospital, the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron Oncology Institute (VHIO), the Multiple Sclerosis Center of Catalonia (CEMCAT) and the Autonomous University of Barcelona.

We are constantly in touch with patients; our starting point is the challenges they present in our day-to-day work to continue to innovate and find new diagnostic methods and treatments. The talented team that has made us a leading institution allows us to work towards attracting excellence and training the best professionals in clinical practice.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Advertising and Marketing, Business, e-Commerce, Free News Articles, Software

AI and Segmentation Leader Fanplayr Continues Global Expansion with New Office Location in Spain

PALO ALTO, Calif. -- Fanplayr, a global leader for e-commerce intelligence solutions, continues to expand its presence in the European market with the opening of a new office in Spain, with the goal of promoting brands that operate in retail, tourism, telecommunications, automotive, banking, energy, insurance and entertainment.

Fanplayr's proprietary, patented predictive marketing technology, using artificial intelligence, enables unprecedented consumer segmentation based on user behavior to drive their clients' growth in eCommerce channels or within their clients' own site. Brands will also benefit from the extension of Fanplayr products that follow up even after a consumer has left the website: emails, SMS notifications, offers and other content of interest.

Even in an uncertain year of COVID and supply chain failures, clients of Fanplayr increased their digital business with Fanplayr products allowing them to improve the conversion rates of their websites for the sale of products or services.

At the head of the Spanish division of Fanplayr is Juan Sevillano, an experienced professional in the AdTech industry for more than two decades. Sevillano has worked for companies such as Yahoo, Microsoft, Amazon and Tradedoubler, including working for Amazon Spain as Head Of AdTech within the Amazon Advertising division. Most recently, Sevillano has served as general director for Spain and Portugal for the Rocket Fuel programmatic purchasing platform and for the global multi-channel ad server Sizmek.

"Our clients are delighted with Fanplayr's behavioral prediction technology," says Juan Sevillano, General Director of Fanplayr in Spain. "The analytical view of customer data coupled with its segmentation capabilities helps customers develop attractive campaigns that achieve a significant increase in their conversion rate, as well as have a profound impact on their overall results."

Simon Yencken, co-founder and CEO of Fanplayr, points out: "Spain is a sufficiently mature market to welcome our predictive technology in key business and financial sectors. And I am sure that the implementation in this region will be something very beneficial for all the innovative brands that operate in Spain and want to offer the best digital experience for their customers."

Learn more at: https://fanplayr.com/

Related link: https://www.fanplayr.com/

This news story was published by the Neotrope® News Network - all rights reserved.